** Hong Kong-listed shares of Chinese oncology treatments developer Beigene Ltd 6160.HK jump 10.1% to HK$117.40
** Stock marks biggest intraday pct rise since December 2022
** Stock hits the highest point since Dec 10, and on course to snap two sessions of decline, if gains hold; stock is fourth-biggest pct gainer in Hang Seng Composite Index .HSCI, which adds 0.9%
** Beigene says it expects to achieve "positive" operating income for full-year 2025 pursuant to U.S. generally accepted accounting principles
** Beigene's Shanghai stock 688235.SS surges 6.7% to 174.18 yuan, its highest since Dec 10
** Hang Seng Commerce & Industry Index .HSNC rises 1.1%, healthcare index .HSCIH surges 2.4% and Hang Seng Index .HSI gains 0.9%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。